Journal of cardiology最新文献

{"title":"HELT-E2S2 vs. CHADS2: Toward a rhythm-integrated stroke risk model post-ablation","authors":"Muhammad Mohid Haroon (MBBS)","doi":"10.1016/j.jjcc.2025.11.011","DOIUrl":"10.1016/j.jjcc.2025.11.011","url":null,"abstract":"","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":"88 2","pages":"Page 146"},"PeriodicalIF":3.5,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145648552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical outcomes and optical coherence tomography findings in myocardial infarction patients without standard modifiable risk factors: Insights from the TACTICS registry","authors":"Hideki Wada MD, PhD,&nbsp;Tomotaka Dohi MD, PhD, FJCC,&nbsp;Manabu Ogita MD, PhD,&nbsp;Satoru Suwa MD,&nbsp;Nobuaki Kobayashi MD, PhD,&nbsp;Masamichi Takano MD, PhD,&nbsp;Seita Kondo MD, PhD,&nbsp;Tomoyo Sugiyama MD, PhD,&nbsp;Tsunekazu Kakuta MD, PhD,&nbsp;Kohei Wakabayashi MD, PhD, FJCC,&nbsp;Hiroyoshi Mori MD, PhD,&nbsp;Shigeki Kimura MD, PhD,&nbsp;Satoru Mitomo MD,&nbsp;Sunao Nakamura MD, PhD, FJCC,&nbsp;Takumi Higuma MD, PhD, FJCC,&nbsp;Junichi Yamaguchi MD, PhD, FJCC,&nbsp;Taishi Yonetsu MD, PhD,&nbsp;Makoto Natsumeda MD,&nbsp;Yuji Ikari MD, PhD, FJCC,&nbsp;Jun Yamashita MD, PhD, FJCC,&nbsp;Toshiro Shinke MD, PhD, FJCC","doi":"10.1016/j.jjcc.2026.01.010","DOIUrl":"10.1016/j.jjcc.2026.01.010","url":null,"abstract":"<div><h3>Background</h3><div>Patients with coronary artery disease who lack any standard modifiable cardiovascular risk factors (SMuRFs; hypertension, diabetes mellitus, dyslipidemia, and smoking) have attracted much attention in recent years due to their unexpectedly poor clinical outcomes. This study aimed to perform optical coherence tomography (OCT)-based evaluation of the characteristics and morphology of coronary culprit lesions of patients with acute myocardial infarction (AMI) but without any SMuRFs, in a prospective multicenter registry.</div></div><div><h3>Methods</h3><div>Patients with AMI diagnosed within 24 h of symptom onset who underwent OCT-guided emergency percutaneous coronary intervention were enrolled. The primary endpoint of the study was to characterize the coronary artery lesions of patients without any SMuRFs.</div></div><div><h3>Results</h3><div>A total of 640 AMI patients were enrolled. Of these, 58 (9%) had no SMuRFs and were in poor clinical condition at presentation, including acute heart failure or cardiogenic shock. OCT found no difference in the morphology of the culprit lesions in terms of presence or absence of SMuRFs. Rates of lipid plaque lesions and plaque calcification &gt;180 degrees were lower in patients without SMuRFs. The risk of cardiovascular events at 12 months was higher in patients without SMuRFs than with SMuRFs (adjusted hazard ratio 2.28, 95% confidence interval 1.13–4.23, <em>p</em> = 0.02).</div></div><div><h3>Conclusions</h3><div>OCT evaluation revealed less lipid plaque and severe calcification in patients without SMuRFs than in those with SMuRFs. This finding indicates that the poor prognosis in the patient group without SMuRFs is due to the poor state of these patients at the time of onset rather than to the morphology of coronary artery lesions.</div></div>","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":"88 2","pages":"Pages 88-94"},"PeriodicalIF":3.5,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146119088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of clinical outcomes between biodegradable polymer sirolimus-eluting stents and durable polymer everolimus-eluting stents in octogenarian patients","authors":"Masaki Kushi MD,&nbsp;Yuichi Ozaki MD, PhD, FJCC,&nbsp;Keiya Komatsu MD,&nbsp;Ryo Hikida MD,&nbsp;Kenichi Komukai MD, PhD,&nbsp;Yosuke Katayama MD, PhD,&nbsp;Keisuke Satogami MD, PhD,&nbsp;Masahiro Takahata MD, PhD,&nbsp;Teruaki Wada MD, PhD,&nbsp;Manabu Kashiwagi MD, PhD,&nbsp;Yasutsugu Shiono MD, PhD,&nbsp;Akio Kuroi MD, PhD,&nbsp;Takashi Yamano MD, PhD,&nbsp;Takashi Tanimoto MD, PhD, FJCC,&nbsp;Shintaro Kuki MD, PhD,&nbsp;Yasushi Ino MD, PhD,&nbsp;Yasushi Hayashi MD,&nbsp;Hironori Kitabata MD, PhD, FJCC,&nbsp;Atsushi Tanaka MD, PhD","doi":"10.1016/j.jjcc.2026.03.015","DOIUrl":"10.1016/j.jjcc.2026.03.015","url":null,"abstract":"<div><h3>Background</h3><div>Biodegradable polymer sirolimus-eluting stents (BP-SESs) have provided similar clinical outcomes including cardiac death, myocardial infarction (MI), and target lesion revascularization to second-generation durable polymer everolimus-eluting stents (DP-EESs). However, safety and efficacy of BP-SES in patients aged ≥80 years remain unknown. The aim of this study was to investigate the 1-year clinical outcomes between BP-SES and DP-EES in patients aged ≥80 years.</div></div><div><h3>Methods</h3><div>We retrospectively analyzed 213 patients aged ≥80 years who underwent percutaneous coronary intervention (PCI) with BP-SES or DP-EES between April 2020 and March 2022. The primary endpoint was a 1-year composite of all-cause death, MI, target vessel revascularization (TVR), cerebrovascular accident (CVA), and definite or probable stent thrombosis (ST). To minimize stent selection bias, propensity score matching was conducted. Multivariable logistic regression was used to identify factors associated with the 1-year primary endpoint in the matched cohort.</div></div><div><h3>Results</h3><div>Among 213 patients treated with BP-SES (<em>n</em> = 93) and DP-EES (<em>n</em> = 120), the 1-year rates of MI, TVR, CVA, ST, and bleeding events were similar between the two groups. After propensity score matching, 1-year event-free survival for the primary endpoint was similar between the BP-SES and DP-EES groups [hazard ratio, 0.893; 95% confidence interval (CI), 0.345–2.315; <em>p</em> = 0.816]. Multivariable analysis demonstrated that acute coronary syndrome [odds ratio (OR), 3.478; 95% CI, 1.019–14.190; <em>p</em> = 0.047] was independently associated with a higher incidence of the 1-year primary endpoint, whereas angiographic success (OR, 0.058; 95% CI, 0.008–0.347; <em>p</em> = 0.002) and angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor blocker use at discharge (OR, 0.229; 95% CI, 0.057–0.858; <em>p</em> = 0.029) were independently associated with a lower incidence.</div></div><div><h3>Conclusions</h3><div>In patients aged ≥80 years, 1-year clinical outcomes after PCI with BP-SES were generally consistent with those with DP-EES.</div></div>","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":"88 2","pages":"Pages 123-128"},"PeriodicalIF":3.5,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147618705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antiplatelet therapy for patients with stable coronary artery disease receiving oral anticoagulation: A meta-analysis of randomized controlled trials","authors":"Yuriko Hiruma MD,&nbsp;Atsuyuki Watanabe MD,&nbsp;Tadao Aikawa MD, PhD,&nbsp;Masao Iwagami MD, PhD,&nbsp;Kaveh Hosseini MD,&nbsp;Leandro Slipczuk MD, PhD,&nbsp;Alexandros Briasoulis MD, PhD,&nbsp;Hisato Takagi MD, PhD,&nbsp;Toshiki Kuno MD, PhD","doi":"10.1016/j.jjcc.2026.05.004","DOIUrl":"10.1016/j.jjcc.2026.05.004","url":null,"abstract":"<div><h3>Background</h3><div>Evidence supporting the discontinuation of antiplatelet therapy in patients with stable coronary artery disease who require anticoagulation remains limited and continues to evolve. This study aimed to assess the efficacy and safety of antithrombotic therapy in this population.</div></div><div><h3>Methods</h3><div>We reviewed randomized controlled trials comparing the efficacy and safety of oral anticoagulant monotherapy versus oral anticoagulant plus single antiplatelet therapy in patients beyond six months after coronary revascularization requiring anticoagulation. The outcomes included major adverse cardiovascular events (MACE) and major bleeding. MACE was defined as a composite of all-cause death, myocardial infarction, stroke, systemic embolism, and revascularization. A pairwise meta-analysis using a random-effects model was conducted.</div></div><div><h3>Results</h3><div>A total of 5924 patients from 6 randomized controlled trials were included: 2970 received oral anticoagulant alone, and 2954 received oral anticoagulant plus single antiplatelet therapy. Anticoagulant monotherapy was associated with a comparable risk of MACE [hazard ratio (HR), 0.80; 95% confidence interval (CI), 0.62–1.04] and a significantly lower major bleeding risk (HR, 0.46; 95% CI, 0.32–0.66) than the combined therapy.</div></div><div><h3>Conclusion</h3><div>Oral anticoagulant alone may be a reasonable strategy to mitigate bleeding risk while preserving an ischemic risk comparable to combined anticoagulant and antiplatelet therapy.</div></div>","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":"88 2","pages":"Pages 136-141"},"PeriodicalIF":3.5,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148004989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to the Editor Re: Association of weekend catch-up sleep, sleep durations and cardiometabolic multimorbidity: Based on NHANES","authors":"Lidong Wang,&nbsp;Jiawei Hu,&nbsp;Xuanfu Ge","doi":"10.1016/j.jjcc.2025.12.010","DOIUrl":"10.1016/j.jjcc.2025.12.010","url":null,"abstract":"","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":"88 2","pages":"Page 148"},"PeriodicalIF":3.5,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145819438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of running average value of non-fasting serum triglyceride for secondary prevention of coronary artery disease","authors":"Ichiro Matsumoto MD,&nbsp;Kensaku Wada MD,&nbsp;Mizuki Kurozumi MD,&nbsp;Tsunetatsu Namba MD,&nbsp;Yuichiro Takagi MD","doi":"10.1016/j.jjcc.2026.03.011","DOIUrl":"10.1016/j.jjcc.2026.03.011","url":null,"abstract":"<div><h3>Background</h3><div>Elevated non-fasting triglyceride (TG) levels may be associated with increased risk of cardiovascular disease (CVD); however, the best way to measure TG values as an independent risk factor for CVD remains unclear. The aim of this study was to investigate whether the running average value of non-fasting serum TG (Ra-TG) measured after percutaneous coronary intervention (PCI) could be associated with the occurrence of subsequent cardiovascular events.</div></div><div><h3>Methods</h3><div>The clinical records of 1761 patients who underwent successful PCI were retrospectively examined. Ra-TG values were calculated by adding consecutive non-fasting serum TG values and dividing them by the number of measurements. Based on the Ra-TG value during the observation period of 10 years after PCI, the patients were divided into 3 groups: Ra-TG ≥175, 115–175, and &lt; 115 mg/dL. The incidence of major adverse cardiac events (MACEs; coronary-related deaths, nonfatal myocardial infarction, and new coronary stenosis of non-culprit lesions) was investigated in these groups. The associations between the incidence of MACEs and various risk factors were also investigated.</div></div><div><h3>Results</h3><div>Kaplan-Meier analysis demonstrated that patients with a Ra-TG ≥175 mg/dL had a significantly higher incidence of MACEs than those in the other two groups. A multivariate analysis indicated that the Ra-TG value was significantly associated with the incidence of MACEs. Furthermore, regardless of patients' low-density lipoprotein cholesterol levels or histories of acute coronary syndrome, a Ra-TG value of more than 175 mg/dL was associated with a higher incidence of MACEs after PCI.</div></div><div><h3>Conclusions</h3><div>A high Ra-TG value is a predictor of increased recurrence of MACEs after PCI and long-term management of TG levels using Ra-TG values may be useful for preventing CVD.</div></div>","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":"88 2","pages":"Pages 129-135"},"PeriodicalIF":3.5,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147529330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of age on the relationship between peak creatine kinase levels and clinical outcomes after ST-elevation myocardial infarction.","authors":"Nao Tamura, Yuichi Saito, Osamu Hashimoto, Takanori Sato, Hideki Kitahara, Yoshio Kobayashi","doi":"10.1016/j.jjcc.2026.07.016","DOIUrl":"10.1016/j.jjcc.2026.07.016","url":null,"abstract":"","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148653904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence and predictors for symptomatic stroke within 30 days after transcatheter aortic valve implantation: insights from the LAPLACE-TAVI registry","authors":"Hiroaki Yokoyama MD, PhD, FJCC,&nbsp;Ken Yamazaki MD, PhD,&nbsp;Shun Shikanai MD, PhD,&nbsp;Misato Hamadate MD, PhD,&nbsp;Michiko Tsushima MD, PhD,&nbsp;Noritomo Narita MD, PhD,&nbsp;Maiko Senoo MD, PhD,&nbsp;Hiroaki Ichikawa MD, PhD,&nbsp;Shuji Shibutani MD, PhD,&nbsp;Kenji Hanada MD, PhD,&nbsp;Yoshiaki Saito MD, PhD,&nbsp;Kenyu Murata MD, PhD,&nbsp;Yuki Imamura MD, PhD,&nbsp;Ryosuke Higuchi MD,&nbsp;Kenichi Hagiya MD,&nbsp;Itaru Takamisawa MD,&nbsp;Mamoru Nanasato MD, PhD, FJCC,&nbsp;Nobuo Iguchi MD, PhD, FJCC,&nbsp;Morimasa Takayama MD, PhD, FJCC,&nbsp;Jun Shimizu MD, PhD,&nbsp;Hirofumi Tomita MD, PhD, FJCC","doi":"10.1016/j.jjcc.2026.02.007","DOIUrl":"10.1016/j.jjcc.2026.02.007","url":null,"abstract":"<div><h3>Background</h3><div>Stroke is a devastating complication after transcatheter aortic valve implantation (TAVI), however contemporary data on its incidence and predictors remain limited.</div></div><div><h3>Methods and results</h3><div>We analyzed 4774 consecutive patients undergoing TAVI between April 2010 and June 2024 in the prospective multicenter LAPLACE-TAVI registry. Patients with valve-in-valve procedures, investigational devices, or missing data were excluded. The primary endpoint was symptomatic stroke within 30 days after TAVI. Patients were stratified into 2 groups: Stroke (<em>n</em> = 68) and non-Stroke groups (<em>n</em> = 4706). Baseline characteristics, TAVI procedural data, and clinical outcomes were compared. Multivariate logistic regression was performed to identify predictors of periprocedural stroke.</div><div>Thirty-day symptomatic stroke occurred in 1.4% of study patients. Stroke patients more frequently had previous stroke, peripheral artery disease (PAD), frailty, and higher Society of Thoracic Surgeons (STS) scores. Nearly 90% of stroke events occurred within 5 days after TAVI. Use of self-expanding (SE) valves was more common in the Stroke group (47% vs. 32%). On multivariate analysis, PAD [odds ratio (OR): 1.70, 95% confidence interval (CI): 1.10–2.63], higher STS score (OR: 1.03, 95%CI: 1.00–1.05), and SE valve use (OR: 1.71, 95%CI: 1.16–2.53) were independent predictors.</div></div><div><h3>Conclusions</h3><div>In this large multicenter registry, the 30-day incidence of symptomatic stroke after TAVI was 1.4%. PAD, higher STS score, and SE valve use were independent predictors. Careful patient selection and procedural planning are warranted.</div></div>","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":"88 2","pages":"Pages 102-108"},"PeriodicalIF":3.5,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147306282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Watchman FLX versus Amplatzer amulet for percutaneous left atrial appendage occlusion: A systematic review and meta-analysis","authors":"Vinicius Bittar de Pontes,&nbsp;Pedro E.P. Carvalho MD,&nbsp;Nicole Felix MD,&nbsp;Alleh Nogueira MD,&nbsp;Mariana R.C. Clemente MD,&nbsp;Victoria Gastaldelo,&nbsp;Alberto Preda MD,&nbsp;Philippe Garot MD","doi":"10.1016/j.jjcc.2025.12.004","DOIUrl":"10.1016/j.jjcc.2025.12.004","url":null,"abstract":"<div><h3>Background</h3><div>The comparative safety and efficacy of Watchman FLX (Boston Scientific, Marlborough, MA, USA) and Amplatzer Amulet (Abbott, Abbott Park, IL, USA) devices for left atrial appendage occlusion (LAAO) remain unclear.</div></div><div><h3>Objective</h3><div>To compare Watchman FLX and Amplatzer Amulet devices for LAAO.</div></div><div><h3>Methods</h3><div>We systematically searched PubMed, Embase, and Cochrane Library for studies comparing Watchman FLX versus Amulet in patients with atrial fibrillation (AF) undergoing percutaneous LAAO. We applied a random-effects model to pool risk ratios (RR) with corresponding 95 % confidence intervals (CI) for binary endpoints.</div></div><div><h3>Results</h3><div>We included five studies comprising 1316 patients with AF undergoing LAAO for high bleeding risk. A total of 629 (47.8 %) patients underwent LAAO with Watchman FLX. Amulet was associated with lower rates of stroke or transient ischemic attack (TIA) (RR 2.31; 95 % CI 1.02–5.25; <em>p</em> = 0.04; I² = 0 %), but no differences were observed in terms of peridevice leak (RR 1.57; 95 % CI 0.86–2.89; <em>p</em> = 0.14; I² = 0 %) between Watchman and Amulet devices. Additionally, no differences were found in terms of device-related thrombus (RR 2.01; 95 % CI 0.87–4.68; <em>p</em> = 0.10; I² = 0 %), or pericardial effusion (RR 1.00; 95 % CI 0.17–5.96; <em>p</em> = 1.00; I² = 59.7 %) between both groups.</div></div><div><h3>Conclusion</h3><div>This meta-analysis indicates a lower risk of stroke or TIA with Amulet compared to Watchman FLX.</div></div>","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":"88 2","pages":"Pages 109-115"},"PeriodicalIF":3.5,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145762816","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Discontinuation of statins by patient and physician sex: An observational study","authors":"Atsuyuki Watanabe MD,&nbsp;Yoshihisa Miyamoto MD, PhD,&nbsp;Hiroki A. Ueyama MD,&nbsp;Hiroshi Gotanda MD, PhD,&nbsp;Leandro Slipczuk MD, PhD,&nbsp;Kosuke Inoue MD, PhD,&nbsp;Eric Secemsky MD,&nbsp;Roger Laham MD,&nbsp;Deepak L. Bhatt MD, MPH, MBA,&nbsp;Yusuke Tsugawa MD, MPH, PhD,&nbsp;Toshiki Kuno MD, PhD","doi":"10.1016/j.jjcc.2026.02.006","DOIUrl":"10.1016/j.jjcc.2026.02.006","url":null,"abstract":"<div><h3>Background</h3><div>This observational study using the national US Medicare claim databases aimed to examine the association of patient and physician sex with statin discontinuation.</div></div><div><h3>Methods</h3><div>We used data on a 20% random sample of Medicare fee-for-service beneficiaries aged 66–99 years who initiated statins for primary prevention (absence of the historical diagnosis of myocardial infarction, ischemic heart disease, stroke, transient ischemic attack, and peripheral vascular disease) from January 2017 to June 2019. The primary outcome was early discontinuation (defined as the lack of second dispense at year 1), adjusting for patient demographics, comorbidities, concomitant medications, and physicians' age and specialty.</div></div><div><h3>Results</h3><div>Of 423,404 patients who initiated statins, 43,053 (10.2%) experienced early discontinuations. The adjusted risk of early discontinuation was similar but slightly lower when initiated by female physicians at 9.9% [95% confidence interval (CI), 9.1 to 10.6] versus male physicians at 10.3% (95% CI, 9.6 to 11.0) with an adjusted risk difference (aRD) of −0.4 percentage-points (pp) (95% CI, −0.7 to −0.2; <em>p</em> &lt; 0.001). When stratified by patient sex, the findings were similar in both female patients (aRD, −0.5 pp.; 95% CI, −0.7 to −0.2; <em>p</em> &lt; 0.001) and male patients (−0.5 pp.; 95% CI, −0.8 to −0.1; <em>p</em> = 0.007). The findings were consistent regardless of the diabetes status or the intensity of statins.</div></div><div><h3>Conclusion</h3><div>Using the nationwide administrative databases, we found that both older female and male patients were slightly less likely to experience early discontinuation of statins when prescribed by female versus male physicians, though the differences were clinically small.</div></div>","PeriodicalId":15223,"journal":{"name":"Journal of cardiology","volume":"88 2","pages":"Pages 116-122"},"PeriodicalIF":3.5,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147306378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}